Prostate Biopsy Medication

1. Becerra MF, Atluri VS, Bhattu AS, Punnen S. Serum and urine biomarkers for detecting clinically significant prostate cancer. Urol Oncol. 2020 Mar 30. [QxMD MEDLINE Link].

2. Liss MA, Ehdaie B, Loeb S, et al. An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol. 2017 Aug. 198 (2):329-34. [QxMD MEDLINE Link].

3. Guideline developed in collaboration with the American College of Radiology, Society of Radiologists in Ultrasound. AIUM Practice Guideline for the Performance of an Ultrasound Evaluation of the Prostate (and Surrounding Structures). J Ultrasound Med. 2015 Aug. 34 (8):1-6. [QxMD MEDLINE Link].

4. Chevli KK, Duff M, Walter P, et al. Urinary PCA3 as a predictor for prostate cancer in a cohort of 3073 men undergoing initial prostate biopsy. J Urol. 2013 Dec 10. [QxMD MEDLINE Link].

5. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol. 2001 Nov. 166(5):1679-83. [QxMD MEDLINE Link].

6. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002 Jun. 167(6):2435-9. [QxMD MEDLINE Link].

7. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000 Apr. 163(4):1144-8; discussion 1148-9. [QxMD MEDLINE Link].

8. Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol. 2000 Jan. 163(1):158-62. [QxMD MEDLINE Link].

9. Lopez-Corona E, Ohori M, Wheeler TM, et al. Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate. J Urol. 2006 Mar. 175(3 Pt 1):923-7; discussion 927-8. [QxMD MEDLINE Link]. [Full Text].

10. Lee MC, Moussa AS, Yu C, Kattan MW, Magi-Galluzzi C, Jones JS. Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. J Urol. 2010 Nov. 184(5):1958-62. [QxMD MEDLINE Link].

11. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 1994 Jun. 151(6):1571-4. [QxMD MEDLINE Link].

12. Kopp RP, Kane CJ, Parsons JK. Preparation for prostate biopsy. Jones JS, ed. Prostate Cancer Diagnosis: PSA, Biopsy and Beyond. Humana Press; 2013. 543.

13. Ching CB, Moussa AS, Li J, Lane BR, Zippe C, Jones JS. Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates. J Urol. 2009 May. 181(5):2077-82; discussion 2082-3. [QxMD MEDLINE Link].

14. Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol. 2012 Apr. 187(4):1275-9. [QxMD MEDLINE Link].

15. Glass A, Punnen S, Shinohara K. Pain prevention. Jones JS, ed. Prostate Cancer Diagnosis: PSA, Biopsy and Beyond. Humana Press; 2013. 543.

16. Issa MM, Bux S, Chun T, Petros JA, Labadia AJ, Anastasia K, et al. A randomized prospective trial of intrarectal lidocaine for pain control during transrectal prostate biopsy: the Emory University experience. J Urol. 2000 Aug. 164(2):397-9. [QxMD MEDLINE Link].

17. Ashley RA, Inman BA, Routh JC, Krambeck AE, Siddiqui SA, Mynderse LA. Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. Cancer. 2007 Oct 15. 110(8):1708-14. [QxMD MEDLINE Link].

18. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997 Jan. 157(1):199-202; discussion 202-3. [QxMD MEDLINE Link].

19. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol. 2004 May. 171(5):1850-4. [QxMD MEDLINE Link].

20. Lefkowitz GK, Sidhu GS, Torre P, Lepor H, Taneja SS. Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling?. Urology. 2001 Dec. 58(6):999-1003. [QxMD MEDLINE Link].

21. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989 Jul. 142 (1):71-4; discussion 74-5. [QxMD MEDLINE Link].

22. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol. 2007 Nov. 52(5):1309-22. [QxMD MEDLINE Link].

23. Zaytoun OM, Anil T, Moussa AS, Jianbo L, Fareed K, Jones JS. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology. 2011 Apr. 77(4):910-4. [QxMD MEDLINE Link].

24. Pinkhasov GI, Lin YK, Palmerola R, et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int. 2012 Feb 7. [QxMD MEDLINE Link].

25. Murray KS, Bailey J, Zuk K, Lopez-Corona E, Thrasher JB. A prospective study of erectile function after transrectal ultrasonography-guided prostate biopsy. BJU Int. 2015 Aug. 116 (2):190-5. [QxMD MEDLINE Link].

26. Mulcahy N. ED Induced by Prostate Biopsy Likely 'Underestimated'. Medscape Medical News. Available at http://www.medscape.com/viewarticle/851957. October 1, 2015; Accessed: April 25, 2016.

Ahmed F El Shafei, MBBCh, MSc(Urol), PhD(Urol) Lecturer of Urology, El Kasr El Aini Hospital, Cairo University, Egypt

Ahmed F El Shafei, MBBCh, MSc(Urol), PhD(Urol) is a member of the following medical societies: European Association of Urology

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Endocare<br/>Received income in an amount equal to or greater than $250 from: Endocare.

J Stephen Jones, MD, MBA, FACS Vice President of Medical Operations, Cleveland Clinic Regional Hospitals and Ambulatory Surgery Centers; Leonard Horvitz and Samuel Miller Distinguished Chair in Urological Oncology Research, Professor of Surgery (Urology), Cleveland Clinic Lerner College of Medicine at Case Western Reserve University

J Stephen Jones, MD, MBA, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Endourological Society, Society of University Urologists, Society of Urologic Oncology, SWOG, International Continence Society

Disclosure: Received honoraria from Cook for consulting; Received honoraria from HealthTronics for speaking and teaching; Received consulting fee from Photocure for other; Received grant/research funds from Analiza for other.

Edward David Kim, MD, FACS Professor of Urology, Department of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American Society for Reproductive Medicine, American Urological Association, Sexual Medicine Society of North America, Society for Male Reproduction and Urology, Society for the Study of Male Reproduction, Tennessee Medical Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Endo, Antares.

• Print this section
• Print the entire contents of
• Print the entire contents of article